A New Hope Before Birth? Landmark Trial Shows Prenatal…

A New Hope Before Birth? Landmark Trial Shows Prenatal Therapy May Improve Survival in Babies With Fetal Kidney Failure For decades, a diagnosis of early fetal kidney failure with anhydramnios, a condition where the baby has little or no amniotic fluid because the kidneys cannot produce urine, has been associated with an extremely poor prognosis. Without enough amniotic fluid, the fetal lungs cannot develop properly, leading to pulmonary hypoplasia, a condition that has historically been almost universally fatal after birth. Now, a landmark clinical trial published in JAMA offers new hope. Researchers from the Renal Anhydramnios Fetal Therapy (RAFT) Clinical Trial have shown that serial amnioinfusions performed during pregnancy can help support fetal lung development, allowing many babies to survive the critical newborn period. While significant medical challenges remain after birth, the findings represent an important advance in fetal therapy. During pregnancy, a baby's kidneys begin producing urine, which becomes the primary source of amniotic fluid in the second half of pregnancy. Amniotic fluid is essential because it: Cushions the fetus Supports normal growth Protects the umbilical cord Most importantly, allows the lungs to develop properly When fetal kidneys fail early in pregnancy, little or no urine is produced, resulting in anhydramnios (absence of amniotic fluid). Without this protective fluid, the lungs cannot expand and mature normally, often leading to severe pulmonary hypoplasia that has traditionally been incompatible with life. Serial amnioinfusion is a fetal therapy in which sterile fluid is repeatedly injected into the amniotic sac during pregnancy. The procedure does not repair the baby's kidneys. Instead, it temporarily restores amniotic fluid levels to create an environment that allows the lungs to continue developing befo